Safety and Efficacy Study of CC312 for Moderate to Severe SLE

This study is a randomized, double-blind, placebo-controlled Phase I clinical trial featuring single and multiple ascending doses. It is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of CC312 in adult patients with moderate to severe systemic lupus erythematosus (SLE).

NCT Number	NCT07177911
Lead Sponsor	CytoCares Inc
Conditions	SLE - Systemic Lupus Erythematosus
Enrollment	32 participants
Start Date	2025-09-11
Primary Completion	2027-09-10 (estimated)
Study Completion	2027-09-10 (estimated)
Updated on ClinicalTrials.gov	2025-09-17